ABSI
Absci Corp
NASDAQ · Healthcare · Biotechnology · US
$7.94
−1.85%Price chart
Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11Sep 16
Key dataSep 16, 2026
Open$8.02
From 52W high−31.67%
Volume65253.00
Market cap$1.36B
P/E (TTM)—
P/S (TTM)872.9x
Div yield—
Key dataSep 16, 2026
Open
$8.02
From 52W high
−31.67%
Volume
65253.00
Market cap
$1.36B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.6x
P/E (TTM)
—
RSI (14)
39.7
MomentumView details →
1D Return
−1.85%
YTD Return
+129.32%
SummaryUpdated Jun 1, 2026
Absci Corporation (NASDAQ:ABSI) is a biotechnology company founded in 2011 and headquartered in Vancouver, Washington. The company went public in July 2021 and operates as a drug and target discovery company that leverages artificial intelligence to create biologic drug candidates. Absci has developed an integrated drug creation platform that unifies traditional drug discovery and cell line development processes, enabling the design of antibodies for previously challenging or "undruggable" targets.
Similar companies
Latest newsMore news →
Eli Lilly is making strategic investments in outside companies such as Absci Corp., which is developing an experimental endometriosis therapy, as part of its expansion into women's health.6d agoAbsci completed a $100 million underwritten offering, including a $40 million strategic investment from Eli Lilly and Company.36d agoAbsci Corporation reported financial and operating results for the second quarter of 2026.36d ago